



02-08-2002



SHEET

101976926

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.	
1. Name of conveying party(ies): Ian Gordan ARMITAGE; Andrew David SEARLE; and Hardev SINGH	2. Name and address of receiving party(ies):
Additional name(s) of conveying party(ies) attached?	Name: SmithKline Beecham Corporation
3. Nature of conveyance: 1-18-02	Internal Address: Corporate Intellectual Property Dept.
X Assignment	Street Address: One Franklin Plaza
Security Agreement	Philadelphia, Pennsylvania 19102
Other	USA
Execution Date: January 21, 2001; March 01, 2001; and March 01, 2001	Additional name(s) & address(es) attached? X No
Application number(s) or patent number(s): 09/744,051 filed on April 20, 2001	
If this document is being filed together with a new application, the Express Mail date of the application is: JAN 18 2002	
A. Patent Application No.(s)	Patent No.(s)
Additional numbers attached?	Yes X No
5. Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved: 1
Name: David J. Levy Patent Counsel	7. Total fee (37 CFR 3.41): \$ 40.00
Internal Address: GlaxoSmithKline	Enclosed
Corporate Intellectual Property	X Authorized to be charged to deposit account
Street Address: Five Moore Drive	8. Deposit account number: 07-1392
PO Box 13398	
City: RTP State: NC Zip: 27709	
DO NOT USE THIS SPACE	
9. Statement and signature. <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i>	
X  Karen L. Prus (Reg. No. 39,337)	 Date
Total number of pages comprising cover sheet: 1 of 1	

02/07/2002 GTDN11 00000234 071392 09744051

01 FC:581

40.00 CH

ASSIGNMENT

WHEREAS I/WE, **Ian Gordon ARMITAGE** residing at 69 Ramerick Gardens, Arlesey, Bedfordshire, SG15 6XZ, United Kingdom, **Andrew David SEARLE** residing at Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom and **Hardev SINGH** residing at Glaxo Wellcome plc, Temple Hill, Dartford, Kent, DA1 5AH, United Kingdom (hereinafter called "the inventor(s)") have invented or discovered "Calcium (3S) tetrahydro-3-furanyl (1S,2R)-3-[[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2(phosphonooxy)propylcarbamate" (hereinafter called "the invention") for which an application for Letters Patent in the United States of America was originally filed as International Application No. PCT.EP99.04991 on 15 July 1999 (hereinafter called "the application"), and

WHEREAS the invention, being made in the circumstances set out in Section 39(1)(a) of the United Kingdom Patents Act 1977, belongs to my/our employer at that time, namely **GLAXO RESEARCH AND DEVELOPMENT LIMITED**, a company incorporated in England whose registered address is Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN, England, and

WHEREAS **GLAXO RESEARCH AND DEVELOPMENT LIMITED** has authorised and requested my/our making the application, and

WHEREAS **GLAXO WELLCOME INC.**, a corporation organised and existing under and by virtue of the laws of the State of North Carolina and having its principal place of business at Five Moore Drive, Research Triangle Park, North Carolina 27709, USA is desirous of acquiring the whole right, title and interest in and to the invention and the application in respect of the United States of America;

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by **GLAXO RESEARCH AND DEVELOPMENT LIMITED** of the invention and the application by operation of law under the United Kingdom Patents Act 1977 and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the

application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to **GLAXO RESEARCH AND DEVELOPMENT LIMITED**. **GLAXO RESEARCH AND DEVELOPMENT LIMITED** in turn hereby assigns and transfers to **GLAXO WELLCOME INC.** its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation, or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and **GLAXO RESEARCH AND DEVELOPMENT LIMITED** hereby authorise and request any patent arising therefrom in the United States of America be issued to **GLAXO WELLCOME INC.**

AND GLAXO RESEARCH AND DEVELOPMENT LIMITED hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **GLAXO WELLCOME INC.**, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

IT is hereby declared that each of the transactions hereby effected does not form part of a larger transaction or of a series of transactions in respect of which the amount or value, or the aggregate amount or value, of the consideration exceeds £60,000.

IN WITNESS whereof and with effect from this 18 July 1998 the inventor(s) and Graham George Brereton as Attorney of **GLAXO RESEARCH AND DEVELOPMENT LIMITED** by virtue of a Power of Attorney granted by **GLAXO RESEARCH AND DEVELOPMENT LIMITED** have hereunto set their respective hands.

SIGNED by Ian Gordon ARMITAGE: 

Date: 21 Jan 2001

in the presence of: PAUL LEE HOPKINS



SIGNED by Andrew David SEARLE:

in the presence of:

SIGNED by Hardev SINGH:

in the presence of:

SIGNED by the said Graham George Brereton as the Attorney of each Glaxo Wellcome plc and Glaxo Research and Development Limited:



ASSIGNMENT

WHEREAS I/WE, Ian Gordon ARMITAGE residing at 69 Ramerick Gardens, Arlesey, Bedfordshire, SG15 6XZ, United Kingdom, **Andrew David SEARLE** residing at Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom and **Hardev SINGH** residing at Glaxo Wellcome plc, Temple Hill, Dartford, Kent, DA1 5AH, United Kingdom (hereinafter called "the inventor(s)") have invented or discovered "Calcium (3S) tetrahydro-3-furanyl (1S,2R)-3-[[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2(phosphonooxy)propylcarbamate" (hereinafter called "the invention") for which an application for Letters Patent in the United States of America was originally filed as International Application No. PCT.EP99.04991 on 15 July 1999 (hereinafter called "the application"), and

WHEREAS the invention, being made in the circumstances set out in Section 39(1)(a) of the United Kingdom Patents Act 1977, belongs to my/our employer at that time, namely **GLAXO RESEARCH AND DEVELOPMENT LIMITED**, a company incorporated in England whose registered address is Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN, England, and

WHEREAS GLAXO RESEARCH AND DEVELOPMENT LIMITED has authorised and requested my/our making the application, and

WHEREAS GLAXO WELLCOME INC., a corporation organised and existing under and by virtue of the laws of the State of North Carolina and having its principal place of business at Five Moore Drive, Research Triangle Park, North Carolina 27709, USA is desirous of acquiring the whole right, title and interest in and to the invention and the application in respect of the United States of America;

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by **GLAXO RESEARCH AND DEVELOPMENT LIMITED** of the invention and the application by operation of law under the United Kingdom Patents Act 1977 and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the

application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to **GLAXO RESEARCH AND DEVELOPMENT LIMITED**. **GLAXO RESEARCH AND DEVELOPMENT LIMITED** in turn hereby assigns and transfers to **GLAXO WELLCOME INC.** its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation, or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and **GLAXO RESEARCH AND DEVELOPMENT LIMITED** hereby authorise and request any patent arising therefrom in the United States of America be issued to **GLAXO WELLCOME INC.**

AND GLAXO RESEARCH AND DEVELOPMENT LIMITED hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **GLAXO WELLCOME INC.**, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

IT is hereby declared that each of the transactions hereby effected does not form part of a larger transaction or of a series of transactions in respect of which the amount or value, or the aggregate amount or value, of the consideration exceeds £60,000.

IN WITNESS whereof and with effect from this 18 July 1998 the inventor(s) and Graham George Brereton as Attorney of **GLAXO RESEARCH AND DEVELOPMENT LIMITED** by virtue of a Power of Attorney granted by **GLAXO RESEARCH AND DEVELOPMENT LIMITED** have hereunto set their respective hands.

SIGNED by Ian Gordon ARMITAGE:

in the presence of:

SIGNED by Andrew David SEARLE:



3/11/01

in the presence of:

NICKOLAS CUTTERHAM

SIGNED by Hardev SINGH:



3/2/01

in the presence of:

IAN GARRY WILLIAMS

SIGNED by the said Graham George Brereton as the Attorney of each Glaxo Wellcome plc and Glaxo Research and Development Limited:

